George Clinical Rebrands to Emerald Clinical Trials: A New Era for Global Research

George Clinical Rebrands to Emerald Clinical Trials

George Clinical, an acclaimed organization in clinical research, recently revealed its new identity as Emerald Clinical Trials. This transformative change, unveiled on April 7, 2025, not only signifies the company’s growth but also emphasizes its mission of enhancing transparency and certainty in global clinical trials.

A Strategic Move

This rebranding marks a pivotal shift for the organization, which has established itself as a trusted Clinical Research Organization (CRO) over the past two decades. The new name reflects Emerald Clinical Trials' unwavering commitment to delivering dependable, flexible services while effectively navigating the complexities of clinical development worldwide.

For over 20 years, the company has honed its expertise, underscoring its capacity to mitigate risks associated with global clinical studies. With a focus on therapeutic areas such as Oncology and Cardio-Reno-Metabolic (CRM), Emerald Clinical Trials is uniquely positioned to make significant contributions to the landscape of clinical research.

Comprehensive Services

Emerald Clinical Trials aims to provide integrated services across various therapeutic disciplines. The organization’s dedication to innovation is evident in its commitment to transforming lives through advanced research methodologies. Operating in 42 countries directly and collaborating with partners in 70 countries, the firm ensures seamless execution of clinical trials on a global scale. This far-reaching presence allows for an efficient and effective approach to research that can adapt to evolving market needs.

Strengthening Relationships

Emerald Clinical Trials’ new brand identity not only amplifies its capabilities but also highlights the depth of its experience to a broader audience. The commitment to maintaining strong relationships with patients, clients, and partners is paramount. By fostering long-term partnerships rooted in trust and reliability, the firm continues to build a reputation for measurable success in the clinical trial landscape.

The operational philosophy at Emerald Clinical Trials centers around the customer’s needs, promising a tailored approach that enables optimal solutions. This commitment is reflected in their impressive track record of repeat clients and industry accolades.

Client Testimonials

Mary Gunn, CEO of Emerald Clinical Trials, shared her perspective on this transformation: “For the past two decades, we have focused on delivering high-quality clinical trials that marry global reach with personalized support. Our strength lies in offering the scale of a large CRO while providing the attentive service of a smaller partner. This blend ensures that every client receives the bespoke support essential for minimizing risks in their clinical programs.”

Dr. Daniel Tillett, CEO of Race Oncology, a client of Emerald, echoed these sentiments, stating, “We intentionally sought a CRO that could provide a flexible approach, meeting the needs of our trials regardless of their complexity. The agility demonstrated by Emerald Clinical Trials is a true asset for biopharmaceutical companies.”

The Future Ahead

Emerald Clinical Trials, based in Singapore, currently supports over 100 biotechnology firms along with 6 of the world’s top 10 pharmaceutical companies. This extensive network is rooted in expertise and scientific excellence, enabling the company to offer comprehensive clinical trial services worldwide, thereby covering all phases of research.

As the clinical research landscape continues to evolve, the rebranding of George Clinical to Emerald Clinical Trials sets a new trajectory for the firm, enhancing its commitment to innovation, client solutions, and impactful research outcomes.

For more information about Emerald Clinical Trials and its services, please visit www.emeraldclinical.com.